Deutsche Bank AG reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Wednesday. They currently have a GBX 5,800 ($71.78) price objective on the biopharmaceutical company’s stock.
Several other research analysts also recently issued reports on AZN. Bryan, Garnier & Co reaffirmed a buy rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Morgan Stanley reaffirmed an overweight rating and set a GBX 5,000 ($61.88) price objective on shares of AstraZeneca plc in a report on Monday, July 11th. Credit Suisse Group AG reaffirmed an underperform rating and set a GBX 4,000 ($49.50) price objective on shares of AstraZeneca plc in a report on Monday, June 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.50) price objective on AstraZeneca plc and gave the stock a sell rating in a report on Tuesday, October 4th. Finally, Jefferies Group upped their price objective on AstraZeneca plc from GBX 4,100 ($50.74) to GBX 4,450 ($55.07) and gave the stock a hold rating in a report on Thursday, June 30th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of GBX 4,937.91 ($61.11).
AstraZeneca plc (LON:AZN) opened at 5074.6807 on Wednesday. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s 50 day moving average price is GBX 5,003.64 and its 200-day moving average price is GBX 4,455.02. The stock’s market cap is GBX 64195.82 billion.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were given a GBX 68.70 ($0.85) dividend. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.